Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2 Multiple Myeloma 1 Lymphoma, B-Cell 1 Hodgkin Disease 1

Interventions

Cyclophosphamide 193 fludarabine phosphate 123 Peripheral Blood Stem Cell Transplantation 107 Etoposide 106 Mycophenolic Acid 95 Filgrastim 92 Doxorubicin 85 Whole-Body Irradiation 84 Tacrolimus 81 Brentuximab Vedotin 80 Melphalan 78 Busulfan 75 Radiotherapy 74 fludarabine 68 Cyclosporine 67 Vinblastine 65 Rituximab 60 Dacarbazine 56 Granulocyte Colony-Stimulating Factor 53 Gemcitabine 52 Antilymphocyte Serum 51 Bleomycin 50 Nivolumab 47 Methotrexate 47 Vincristine 46 Prednisone 45 Cytarabine 44 pembrolizumab 36 Carmustine 36 Bendamustine Hydrochloride 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hodgkin Disease × Lenograstim × Lymphoid × Clear all

NCT01085058 2010-03-11

CU01

WiSP Wissenschaftlicher Service Pharma GmbH

Phase 2/3 Completed

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡